Latest Market Expansion News

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Love Group Global Ltd reported a 15% decline in quarterly customer cash receipts to $884k in Q3 FY26, driven by a sharp drop in Hong Kong. Despite this, the company maintained positive net operating cash flow and is pursuing growth in US and UK markets.

Comvita launches a NZ$30 million renounceable Rights Offer to refinance debt and bring Southeast Asian consumer giant Fraser and Neave onboard as a strategic investor with a near 20% stake.

Senetas Corporation has landed a landmark US$1.7 million deal with a new South American government client, marking its biggest virtual encryption sale and expanding its global footprint. The company also finalised a delayed Middle East transaction, collectively boosting FY2026 profit expectations.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

PARKD Ltd has secured a $220,000 strategic investment from NSW concrete heavyweight Azzurri Concrete, reinforcing its modular construction push in the state and complementing its existing Queensland partnership.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

SPC Global Holdings Limited reported continued improvement in Q3 FY26, with net sales revenue and normalised EBITDA on track to meet full-year guidance. The company is progressing with its Mill Park facility closure and expanding its international footprint, particularly in Asia.

DroneShield Limited has appointed Angus Bean as its new CEO and Hamish McLennan as Chairman, following the departures of Oleg Vornik and Peter James. The company also reported record cash receipts of $77 million in the first quarter of 2026, reflecting strong growth momentum.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.